The clinical presentation of patients suffering from Laron syndrome, occurring due to growth hormone (GH) insensitivity, is diverse, but the two most important features are dwarfism and obesity [1] [2]. The majority of patients exhibit short stature from birth, and a progressive deficit in growth and development throughout childhood leads to finite body heights between 4 and 10 height standard deviations (SDs) below the average for appropriate age [1]. In addition, very small hands and feet (known as acromicria) are observed, as well as short limbs compared to the size of the trunk [1]. Obesity is progressive, despite the fact that the caloric intake is normal or even reduced, and occurs on the grounds of reduced muscle and bone content [1]. It often predisposes patients to sleep apnea, skin wrinkling and joint pain as a result of poor muscle strength, which may be quite debilitating [1] [2] [3]. Genital and hormonal abnormalities, such as hypogonadism and underdevelopment of the genital organs (or hypogenitalism, manifesting as micropenis, small testes, and reduced ovarian size, respectively) are frequent findings in children suffering from this genetic disorder. Moreover, puberty is often delayed, and secondary sexual characteristics typically develop later in adolescence [1] [3] [4]. Facial changes, including protrusion of the forehead, a saddle nose, hypoplasia of the mandible and other facial bones, thin hair and delayed teething are common features as well [1] [5]. Delayed nail growth and blue sclerae may also be present [1].

The diagnosis of Laron syndrome can be difficult to attain without a thorough patient history and a meticulous physical examination. The autosomal recessive nature of the disorder may be the reason why it is identified almost exclusively in families with consanguineous marriages, and the majority of patients are of Middle-Eastern or Mediterranean origin [1] [2]. For this reason, the presence of similar symptoms and signs in among close relatives or siblings may be a valuable clue toward the diagnosis, whereas a complete physical examination provides sufficient clinical criteria to assume impaired growth hormone activity. Basic laboratory workup should include estimation of glucose levels, as many patients suffer from hypoglycemia, the later development of diabetes mellitus and insulin intolerance, together with serum alkaline phosphatase (ALP), creatinine, a full lipid profile, and hormonal assessment [1]. Paradoxically, growth hormone (GH) levels are normal or markedly elevated when exogenous stimulation is performed, but the values of insulin-like growth factor 1 (IGF-1) are quite low, which serves as one of the key regulators of GH activity [1]. Low IGF-1 levels are thought to explain the mild pancytopenia that is observed in patients, due to its potential role in erythropoiesis [1]. Imaging studies, such as plain radiography and computed tomography (CT), could be used to assess skeletal and soft-tissue changes, respectively. Even though the diagnosis is often made based on clinical and laboratory criteria [3] [6], genetic studies should be carried out, if possible, in order to confirm GH insensitivity [1].

There is no cure for Laron Syndrome, but treatment focuses on managing symptoms and improving quality of life. Recombinant IGF-1 therapy can be administered to promote growth and development. Regular monitoring by a healthcare team, including endocrinologists and nutritionists, is crucial to address any associated health issues, such as hypoglycemia or delayed puberty.

The prognosis for individuals with Laron Syndrome is generally good, with a normal life expectancy. While short stature is a lifelong characteristic, early intervention with IGF-1 therapy can help improve growth outcomes. Regular medical follow-up is important to manage any potential complications and ensure overall well-being.

Laron Syndrome is caused by mutations in the GHR gene, which is responsible for producing the growth hormone receptor. These mutations lead to a lack of functional receptors, preventing growth hormone from exerting its effects on the body. The condition is inherited in an autosomal recessive pattern, meaning both copies of the gene in each cell have mutations.

Laron Syndrome is an extremely rare condition, with only a few hundred cases reported worldwide. It is more prevalent in certain populations, such as in some Middle Eastern and Mediterranean communities. The rarity of the condition makes it challenging to study extensively, but ongoing research continues to provide insights into its genetic and clinical aspects.

In Laron Syndrome, the body's inability to respond to growth hormone results from defective growth hormone receptors. This leads to low levels of IGF-1, a hormone crucial for normal growth and development. The lack of IGF-1 affects various tissues and organs, resulting in the characteristic features of the syndrome, such as short stature and delayed puberty.

Currently, there is no known way to prevent Laron Syndrome, as it is a genetic condition. Genetic counseling is recommended for families with a history of the disorder to understand the risks and implications of passing the condition to future generations. Prenatal testing may be available for at-risk pregnancies to detect the presence of GHR gene mutations.

Laron Syndrome is a rare genetic disorder caused by mutations in the growth hormone receptor gene, leading to growth hormone insensitivity. It is characterized by short stature and other distinctive physical features. While there is no cure, treatment with IGF-1 can help manage symptoms and improve growth outcomes. Early diagnosis and regular medical follow-up are essential for optimal care.

For patients and families affected by Laron Syndrome, understanding the condition is crucial. It is important to know that while the syndrome results in short stature, individuals can lead healthy and fulfilling lives with appropriate medical care. Treatment options, such as IGF-1 therapy, can help improve growth and development. Support from healthcare professionals, genetic counselors, and patient advocacy groups can provide valuable resources and guidance.

1. Laron Z. Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003. J Clin Endocrinol Metab. 2004;89(3):1031-1044.
2. Kanety H, Hemi R, Ginsberg S, et al. Total and high molecular weight adiponectin are elevated in patients with Laron syndrome despite marked obesity. Eur J Endocrinol. 2009;161(6):837-844.
3. Phanse-Gupte SR, Khadilkar VV, Khadilkar AV. Clinical features and endocrine profile of Laron syndrome in Indian children. Indian J Endocrinol Metab. 2014;18(6):863-867.
4. Goswami S, Ghosh S, Chowdhury S. Growth hormone insensitivity syndrome: A sensitive approach. Indian J Endocrinol Metab. 2012;16(5):817-818.
5. Cotta OR, Santarpia L, Curtò L, et al. Primary growth hormone insensitivity (Laron syndrome) and acquired hypothyroidism: a case report. J Med Case Reports. 2011;5:301.
6. Guleria S, Sharma J, Kaushik SL. Laron syndrome. J Postgrad Med. 2014;60(3):322-323.